Q4 2025 argenx SE Earnings Call Transcript
Key Points
- argenx SE (ARGNF) reported a significant year-over-year growth of 90% in net sales, reaching $4.2 billion for the full year 2025.
- The company successfully launched a pre-filled syringe for self-injection, which has been a key driver in increasing demand for Vivguard.
- Positive results from the phase 3 Adapt Oculus study for ocular myasthenia gravis (MG) were announced, marking a significant milestone for patients with limited treatment options.
- argenx SE (ARGNF) achieved its first year of annual operating profitability with an operating profit of $1.1 billion.
- The company has a strong cash balance of $4.4 billion, providing a solid foundation for future investments in commercial growth and pipeline development.
- Operating expenses increased by $149 million in the fourth quarter, totaling $955 million, which may impact future profitability if not managed carefully.
- The company anticipates continued growth in operating expenses in 2026, which could pressure margins if revenue growth does not keep pace.
- Despite the positive results, the company faces potential challenges in expanding payer coverage and securing reimbursement for new indications like ocular MG.
- argenx SE (ARGNF) is still in the early stages of its CIDP launch, indicating that significant market penetration and revenue growth in this area may take time.
- The company faces emerging competition in the myasthenia gravis market, which could impact its market share and growth trajectory.
Good morning. My name is Ram, and I will be your conference operator today. I would like to welcome everyone to the call. At this time, all lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session.
Thank you. I'd now like to introduce Beth Del Jacko, Vice President of Corporate Affairs. You may now begin your conference.
Thank you. Two press releases were issued earlier today. One sharing the positive results from our phase 3 Adapt Oculus study, and the other which outlines our fourth quarter and full year 2025 financial results and business update. These can be found on our website along with the presentation for today's webcast.
Before we begin on slide 2, I'd like to remind you that forward-looking statements may be presented during this call.
These may include statements about our future expectations, clinical development, regulatory timeline, the potential
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
